Cargando…
Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa
BACKGROUND: Escherichia coli is considered a leading bacterial trigger of inflammatory bowel disease (IBD). E. coli isolates from IBD patients primarily belong to phylogroup B2. Previous studies have focused on broad comparative genomic analysis of E. coli B2 isolates, and identified virulence facto...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996543/ https://www.ncbi.nlm.nih.gov/pubmed/29890970 http://dx.doi.org/10.1186/s12918-018-0587-5 |
_version_ | 1783330886580699136 |
---|---|
author | Fang, Xin Monk, Jonathan M. Mih, Nathan Du, Bin Sastry, Anand V. Kavvas, Erol Seif, Yara Smarr, Larry Palsson, Bernhard O. |
author_facet | Fang, Xin Monk, Jonathan M. Mih, Nathan Du, Bin Sastry, Anand V. Kavvas, Erol Seif, Yara Smarr, Larry Palsson, Bernhard O. |
author_sort | Fang, Xin |
collection | PubMed |
description | BACKGROUND: Escherichia coli is considered a leading bacterial trigger of inflammatory bowel disease (IBD). E. coli isolates from IBD patients primarily belong to phylogroup B2. Previous studies have focused on broad comparative genomic analysis of E. coli B2 isolates, and identified virulence factors that allow B2 strains to reside within human intestinal mucosa. Metabolic capabilities of E. coli strains have been shown to be related to their colonization site, but remain unexplored in IBD-associated strains. RESULTS: In this study, we utilized pan-genome analysis and genome-scale models (GEMs) of metabolism to study metabolic capabilities of IBD-associated E. coli B2 strains. The study yielded three results: i) Pan-genome analysis of 110 E. coli strains (including 53 isolates from IBD studies) revealed discriminating metabolic genes between B2 strains and other strains; ii) Both comparative genomic analysis and GEMs suggested that B2 strains have an advantage in degrading and utilizing sugars derived from mucus glycan, and iii) GEMs revealed distinct metabolic features in B2 strains that potentially allow them to utilize energy more efficiently. For example, B2 strains lack the enzymes to degrade amadori products, but instead rely on neighboring bacteria to convert these substrates into a more readily usable and potentially less sought after product. CONCLUSIONS: Taken together, these results suggest that the metabolic capabilities of B2 strains vary significantly from those of other strains, enabling B2 strains to colonize intestinal mucosa.The results from this study motivate a broad experimental assessment of the nutritional effects on E. coli B2 pathophysiology in IBD patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12918-018-0587-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5996543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59965432018-06-25 Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa Fang, Xin Monk, Jonathan M. Mih, Nathan Du, Bin Sastry, Anand V. Kavvas, Erol Seif, Yara Smarr, Larry Palsson, Bernhard O. BMC Syst Biol Research Article BACKGROUND: Escherichia coli is considered a leading bacterial trigger of inflammatory bowel disease (IBD). E. coli isolates from IBD patients primarily belong to phylogroup B2. Previous studies have focused on broad comparative genomic analysis of E. coli B2 isolates, and identified virulence factors that allow B2 strains to reside within human intestinal mucosa. Metabolic capabilities of E. coli strains have been shown to be related to their colonization site, but remain unexplored in IBD-associated strains. RESULTS: In this study, we utilized pan-genome analysis and genome-scale models (GEMs) of metabolism to study metabolic capabilities of IBD-associated E. coli B2 strains. The study yielded three results: i) Pan-genome analysis of 110 E. coli strains (including 53 isolates from IBD studies) revealed discriminating metabolic genes between B2 strains and other strains; ii) Both comparative genomic analysis and GEMs suggested that B2 strains have an advantage in degrading and utilizing sugars derived from mucus glycan, and iii) GEMs revealed distinct metabolic features in B2 strains that potentially allow them to utilize energy more efficiently. For example, B2 strains lack the enzymes to degrade amadori products, but instead rely on neighboring bacteria to convert these substrates into a more readily usable and potentially less sought after product. CONCLUSIONS: Taken together, these results suggest that the metabolic capabilities of B2 strains vary significantly from those of other strains, enabling B2 strains to colonize intestinal mucosa.The results from this study motivate a broad experimental assessment of the nutritional effects on E. coli B2 pathophysiology in IBD patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12918-018-0587-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-11 /pmc/articles/PMC5996543/ /pubmed/29890970 http://dx.doi.org/10.1186/s12918-018-0587-5 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Fang, Xin Monk, Jonathan M. Mih, Nathan Du, Bin Sastry, Anand V. Kavvas, Erol Seif, Yara Smarr, Larry Palsson, Bernhard O. Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
title | Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
title_full | Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
title_fullStr | Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
title_full_unstemmed | Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
title_short | Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
title_sort | escherichia coli b2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996543/ https://www.ncbi.nlm.nih.gov/pubmed/29890970 http://dx.doi.org/10.1186/s12918-018-0587-5 |
work_keys_str_mv | AT fangxin escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT monkjonathanm escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT mihnathan escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT dubin escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT sastryanandv escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT kavvaserol escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT seifyara escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT smarrlarry escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa AT palssonbernhardo escherichiacolib2strainsprevalentininflammatoryboweldiseasepatientshavedistinctmetaboliccapabilitiesthatenablecolonizationofintestinalmucosa |